Eikon Therapeutics, Inc.
EIKN
$15.05
$0.221.48%
NASDAQ
| 12/31/2024 | |||||
|---|---|---|---|---|---|
| Revenue | -- | ||||
| Total Other Revenue | -- | ||||
| Total Revenue | -- | ||||
| Cost of Revenue | -- | ||||
| Gross Profit | -- | ||||
| SG&A Expenses | 13.92M | ||||
| Depreciation & Amortization | -- | ||||
| Other Operating Expenses | -- | ||||
| Total Operating Expenses | 67.78M | ||||
| Operating Income | -67.78M | ||||
| Income Before Tax | -64.92M | ||||
| Income Tax Expenses | -- | ||||
| Earnings from Continuing Operations | -64.92M | ||||
| Earnings from Discontinued Operations | -- | ||||
| Extraordinary Item & Accounting Change | -- | ||||
| Minority Interest in Earnings | -- | ||||
| Net Income | -64.92M | ||||
| EBIT | -67.78M | ||||
| EBITDA | -64.00M | ||||
| EPS Basic | -24.34 | ||||
| Normalized Basic EPS | -15.21 | ||||
| EPS Diluted | -24.34 | ||||
| Normalized Diluted EPS | -15.21 | ||||
| Average Basic Shares Outstanding | 2.67M | ||||
| Average Diluted Shares Outstanding | 2.67M | ||||
| Dividend Per Share | -- | ||||
| Payout Ratio | -- | ||||